Pancreatic Disorders: Acute and Chronic Pancreatitis, Pancreatic Cancer, and Exocrine Function

The pancreas is a dual-function organ consisting of exocrine (95%) and endocrine (5%) components. The exocrine pancreas secretes 1.5-2 liters of alkaline pancreatic juice daily, containing digestive enzymes and bicarbonate. The main pancreatic duct (Wirsung) joins the common bile duct to form the ampulla of Vater, which opens into the duodenum.

Exocrine Function: Acinar cells produce digestive enzymes stored in zymogen granules:

• Proteases: Trypsinogen, chymotrypsinogen, proelastase (activated by enterokinase)
• Lipases: Pancreatic lipase, phospholipase A2
• Carbohydrases: α-amylase
• Nucleases: Ribonuclease, deoxyribonuclease

Ductal cells secrete bicarbonate-rich fluid (pH 8.0-8.5) stimulated by secretin. The bicarbonate neutralizes gastric acid, creating optimal pH for enzyme function.

Regulatory Mechanisms:

1. Cephalic phase: Vagal stimulation increases enzyme secretion
2. Gastric phase: Gastrin stimulates enzyme release
3. Intestinal phase: CCK (cholecystokinin) stimulates enzyme secretion; secretin stimulates bicarbonate release

Clinical Correlation: Pancreatic insufficiency occurs when >90% of exocrine function is lost, leading to maldigestion and steatorrhea. Normal pancreatic elastase levels (>200 μg/g stool) indicate adequate exocrine function, while levels <100 μg/g suggest severe insufficiency.

The pancreas has limited regenerative capacity compared to the liver, making it vulnerable to progressive damage from inflammation or obstruction.

Acute pancreatitis is an inflammatory condition characterized by premature activation of pancreatic enzymes within the gland, leading to autodigestion and tissue damage.

Pathophysiology: The "common channel theory" explains most cases: obstruction at the ampulla of Vater causes bile reflux into the pancreatic duct, activating trypsinogen. Once activated, trypsin triggers a cascade:

1. Activation of other pancreatic enzymes
2. Complement and kinin systems activation
3. Release of inflammatory mediators (TNF-α, IL-1, IL-6)
4. Increased vascular permeability and systemic inflammatory response

Etiologies (GET SMASHED mnemonic):

• Gallstones (40-60% of cases)
• Ethanol (20-30%)
• Trauma
• Steroids, Sphincter of Oddi dysfunction
• Mumps, Malignancy
• Autoimmune
• Scorpion bites, Surgery
• Hyperlipidemia, Hypercalcemia
• ERCP
• Drugs (azathioprine, didanosine, furosemide, pentamidine)

Clinical Presentation:

• Severe epigastric pain radiating to the back
• Pain improved by leaning forward or fetal position
• Nausea and vomiting
• Abdominal distension
• Fever and tachycardia

Physical Findings:

• Epigastric tenderness with guarding
• Cullen's sign (periumbilical ecchymosis)
• Grey Turner's sign (flank ecchymosis)
• Both signs indicate retroperitoneal hemorrhage (present in <5% of cases)

Laboratory Findings:

• Serum lipase: >3x upper normal (more specific than amylase)
• Serum amylase: >3x upper normal (peaks at 24 hours, normalizes in 3-5 days)
• Elevated ALT (>150 U/L suggests gallstone etiology)
• Hypocalcemia, hyperglycemia
• Elevated LDH, decreased albumin

Diagnosis requires 2 of 3 criteria: characteristic pain, elevated enzymes (lipase/amylase >3x normal), or imaging findings consistent with pancreatitis.

Early severity assessment is crucial for management and prognosis. Multiple scoring systems help predict outcomes and guide therapeutic decisions.

Severity Classification:

Scoring Systems:

Ranson's Criteria (≥3 predicts severe disease): At admission:

• Age >55 years
• WBC >16,000/μL
• Glucose >200 mg/dL (11.1 mmol/L)
• LDH >350 U/L
• AST >250 U/L

At 48 hours:

• Hematocrit drop >10%
• BUN rise >5 mg/dL (1.8 mmol/L)
• Calcium <8 mg/dL (2 mmol/L)
• PaO2 <60 mmHg
• Base deficit >4 mEq/L
• Fluid sequestration >6L

APACHE-II Score (≥8 indicates severe disease) BISAP Score (≥3 indicates severe disease):

• BUN >25 mg/dL
• Impaired mental status
• SIRS (≥2 criteria)
• Age >60 years
• Pleural effusion

Local Complications:

1. Acute fluid collections: Develop within 4 weeks, lack wall
2. Pseudocysts: Mature collections with fibrous wall (>4 weeks)
3. Acute necrotic collections: Necrosis within 4 weeks
4. Walled-off necrosis: Mature necrotic collection with wall

Systemic Complications:

• ARDS (acute respiratory distress syndrome)
• Acute kidney injury
• Cardiovascular shock
• DIC (disseminated intravascular coagulation)
• Multi-organ failure

Management Principles:

• Aggressive fluid resuscitation (Ringer's lactate 5-10 mL/kg/h)
• Pain control
• NPO initially, early enteral feeding when tolerated
• ERCP with sphincterotomy for gallstone pancreatitis with cholangitis
• Antibiotics only for infected necrosis or cholangitis

Chronic pancreatitis is a progressive inflammatory disease characterized by irreversible structural damage, fibrosis, and eventual loss of exocrine and endocrine function.

Pathophysiology: The "necrosis-fibrosis hypothesis" suggests repeated episodes of acute pancreatitis lead to chronic changes. However, chronic pancreatitis can develop without prior acute episodes. Key mechanisms include:

1. Persistent inflammation and oxidative stress
2. Activated pancreatic stellate cells producing excessive collagen
3. Progressive ductal strictures and calcifications
4. Acinar cell atrophy and replacement with fibrous tissue

Etiologies:

• Alcohol (70-80% in Western countries): Requires 4-5 drinks/day for 5+ years
• Genetic mutations: CFTR, PRSS1, SPINK1, CTRC
• Autoimmune pancreatitis: IgG4-related disease
• Tropical pancreatitis: Nutritional factors, cassava consumption
• Hereditary pancreatitis: PRSS1 mutations (cationic trypsinogen)
• Idiopathic: 10-30% of cases

Clinical Presentation: Pain Pattern:

• Initially episodic, becomes constant
• Epigastric pain radiating to back
• "Burnout" phase: pain decreases as gland burns out

Exocrine Insufficiency (>90% function lost):

• Steatorrhea: bulky, foul-smelling, floating stools
• Fat-soluble vitamin deficiencies (A, D, E, K)
• Weight loss and malnutrition
• Protein maldigestion (less common than fat maldigestion)

Endocrine Insufficiency:

• Diabetes mellitus (30-80% of patients)
• Brittle diabetes due to loss of both insulin and glucagon
• Increased hypoglycemia risk

Diagnostic Tests:

Management: Pain Control:

• Celiac plexus blocks
• Pancreatic enzymes (may reduce pain)
• Analgesics (avoid opioid dependence)
• Surgical options: lateral pancreaticojejunostomy (Puestow), pancreaticoduodenectomy

Exocrine Replacement:

• Pancreatic enzyme replacement therapy (PERT)
• Dosing: 25,000-50,000 units lipase with meals
• Take with first bite of food
• Proton pump inhibitors to optimize pH

Endocrine Management:

• Diabetes management with insulin
• Monitor for hypoglycemia (glucagon deficiency)
• Fat-soluble vitamin supplementation

Pancreatic adenocarcinoma is an aggressive malignancy with a 5-year survival rate of <10%. It represents 95% of pancreatic cancers and is the fourth leading cause of cancer death.

Epidemiology:

• Incidence: 13-14 per 100,000 annually
• Peak age: 60-80 years
• Male predominance (1.3:1)
• Higher incidence in African Americans
• Geographic variation: higher in developed countries

Risk Factors:

Other factors: Age >50, obesity, high-fat diet, occupational exposures (pesticides, dyes)

Molecular Pathogenesis: Pancreatic cancer develops through accumulation of genetic alterations:

Driver Mutations:

1. KRAS (95% of cases): Early event, promotes cell proliferation
2. TP53 (70%): Loss of tumor suppressor function
3. SMAD4/DPC4 (50%): Loss of TGF-β pathway control
4. CDKN2A (90%): Cell cycle checkpoint loss

Progression Model: Normal epithelium → PanIN-1A → PanIN-1B → PanIN-2 → PanIN-3 → Invasive carcinoma

PanIN Classification:

• PanIN-1A: Flat lesions with mucinous differentiation
• PanIN-1B: Papillary architecture
• PanIN-2: Nuclear abnormalities, loss of polarity
• PanIN-3: Severe dysplasia, carcinoma in situ

Tumor Biology:

• Dense desmoplastic stroma (up to 80% of tumor volume)
• Hypovascular and hypoxic microenvironment
• Extensive neural invasion
• Early metastatic spread
• Resistance to chemotherapy and radiation

Location Distribution:

• Head: 65-70% (present earlier due to biliary obstruction)
• Body/tail: 30-35% (present later, worse prognosis)

Metastatic Pattern:

• Liver (most common)
• Peritoneum
• Lungs
• Bone (uncommon)

The poor prognosis reflects late presentation (80% have metastatic or locally advanced disease at diagnosis), aggressive biology, and resistance to current therapies.

Pancreatic cancer typically presents with nonspecific symptoms, leading to delayed diagnosis. Early detection remains challenging due to the retroperitoneal location and lack of effective screening methods.

Clinical Presentation by Location:

Head of Pancreas (65-70%):

• Painless jaundice (Courvoisier's law: palpable, non-tender gallbladder with jaundice suggests malignant obstruction)
• Progressive jaundice with dark urine and clay-colored stools
• Pruritus due to bile salt deposition
• Weight loss (present in 90% at diagnosis)
• Abdominal pain (85%): epigastric, radiating to back
• New-onset diabetes (10-20%)

Body/Tail (30-35%):

• Epigastric/back pain (more prominent than head lesions)
• Weight loss and anorexia
• Late-onset diabetes
• Splenomegaly (splenic vein thrombosis)
• Left-sided varicocele (left renal vein compression)

Constitutional Symptoms:

• Fatigue and weakness
• Depression (can precede other symptoms)
• Thromboembolism (Trousseau's syndrome)
• Migratory thrombophlebitis

Physical Findings:

• Jaundice and scleral icterus
• Palpable gallbladder (Courvoisier's sign)
• Epigastric mass (advanced disease)
• Hepatomegaly
• Ascites
• Supraclavicular lymphadenopathy (Virchow's node)
• Sister Mary Joseph nodule (umbilical metastasis)

Laboratory Studies:

Imaging Approach:

First-line: CT Pancreatic Protocol

• Pancreatic phase (40-50 seconds post-contrast)
• Arterial and venous phases
• Identifies mass, vascular involvement, metastases
• Sensitivity: 85-95% for masses >2 cm

MRI/MRCP:

• Better soft tissue contrast
• Evaluates biliary and pancreatic ducts
• Useful when CT is inconclusive
• No radiation exposure

Endoscopic Ultrasound (EUS):

• Most sensitive for small tumors (<2 cm)
• Allows tissue sampling (EUS-FNA)
• Evaluates vascular invasion
• Staging accuracy: 85-95%

ERCP:

• Diagnostic: biliary stricture, pancreatic duct irregularities
• Therapeutic: biliary stenting
• Brush cytology from strictures
• Risk of pancreatitis (5-10%)

Tissue Diagnosis: Histological confirmation required before treatment:

• EUS-guided FNA (preferred)
• CT-guided percutaneous biopsy
• ERCP with brush cytology
• Laparoscopic biopsy

Note: Avoid percutaneous biopsy if surgical resection planned (risk of peritoneal seeding).

Clinical Vignette 1: Acute Pancreatitis

A 45-year-old woman presents to the emergency department with severe epigastric pain radiating to her back, which started 6 hours ago after a fatty meal. She describes the pain as 9/10, constant, and partially relieved by leaning forward. She has nausea, vomited twice, and appears diaphoretic. Past medical history includes gallstones diagnosed 2 years ago but never treated.

Physical examination: Temperature 101.2°F (38.4°C), HR 110 bpm, BP 95/60 mmHg. Epigastric tenderness with guarding, hypoactive bowel sounds, no rebound tenderness.

Laboratory results: Lipase 850 U/L (normal <60), Amylase 420 U/L (normal <100), WBC 14,000/μL, ALT 180 U/L, Total bilirubin 3.2 mg/dL, Calcium 7.8 mg/dL.

Discussion: This case demonstrates classic gallstone pancreatitis. Key diagnostic features include:

1. Clinical presentation: Severe epigastric pain radiating to back, postprandial onset
2. Laboratory findings: Elevated lipase >3x normal (more specific than amylase), ALT >150 U/L suggests gallstone etiology
3. Risk stratification: Ranson's criteria = 1 (WBC >16,000 = No, Age >55 = No, others negative initially)

Management approach:

• Aggressive IV fluid resuscitation (Ringer's lactate)
• Pain control with opioids
• NPO initially
• ERCP with sphincterotomy if cholangitis develops
• Cholecystectomy during same hospitalization if mild pancreatitis

Clinical Vignette 2: Pancreatic Adenocarcinoma

A 68-year-old male smoker presents with progressive fatigue, 15-pound weight loss over 3 months, and recent onset of diabetes requiring insulin. He notes mild, intermittent epigastric discomfort and has developed jaundice over the past week with dark urine and pale stools. He denies fever, nausea, or significant abdominal pain.

Physical examination: Jaundiced appearance, palpable non-tender right upper quadrant mass, no hepatosplenomegaly.

Laboratory results: Total bilirubin 8.5 mg/dL, Direct bilirubin 6.2 mg/dL, Alkaline phosphatase 420 U/L, ALT 95 U/L, CA 19-9 850 U/mL, Glucose 280 mg/dL.

Imaging: CT shows 3-cm hypoenhancing mass in pancreatic head with biliary ductal dilation and no obvious metastases.

Discussion: This presentation is highly suspicious for pancreatic head adenocarcinoma:

1. Risk factors: Age >60, smoking history, new-onset diabetes
2. Classic triad: Painless jaundice, weight loss, new diabetes (present in <10% but highly specific)
3. Laboratory: Marked cholestatic pattern, elevated CA 19-9
4. Physical findings: Palpable mass suggests Courvoisier's sign

Next steps:

1. Staging: Chest CT, consider PET scan
2. EUS with FNA: Tissue diagnosis and local staging
3. Multidisciplinary evaluation: Surgery, oncology, gastroenterology
4. Resectability assessment: Vascular involvement evaluation

Prognosis: If resectable, 5-year survival 15-25%; if unresectable, median survival 6-11 months with chemotherapy.